Medacta Group SA
SIX:MOVE

Watchlist Manager
Medacta Group SA Logo
Medacta Group SA
SIX:MOVE
Watchlist
Price: 170 CHF 1.92% Market Closed
Market Cap: 3.4B CHF

Medacta Group SA
Investor Relations

Medacta Group SA, hailing from the picturesque setting of Castel San Pietro, Switzerland, stands as a prominent player in the global medical technology arena. Founded in 1999, the company has capitalized on a family-driven passion for innovation and precision in the orthopedic industry. Guided by its roots, Medacta designs and supplies orthopedic implants and surgical instruments, with a staunch focus on products for joint replacement, spine surgery, and sports medicine. But beyond mere manufacturing, Medacta combines cutting-edge research with in-depth medical training programs, ensuring that healthcare professionals are not only equipped with superior products but also with the necessary skills to optimize patient outcomes. The company’s MyPractice Development Plan exemplifies this by pairing technical support with educational efforts, fostering both confidence and competence among its professional clients.

Medacta’s business model is a synthesis of product sales and continuous practitioner engagement. Revenue streams primarily flow from the direct sale of their extensive product portfolio, including implants and surgical instruments, to hospitals and surgical centers. However, Medacta's strategy extends its competitive advantage by nurturing strong relationships with medical professionals through training and support initiatives. This symbiotic approach ensures a feedback loop that not only tailors their offerings to the evolving needs of the marketplace but also solidifies client loyalty. Their innovative and educational initiatives secure a unique position in the market, allowing Medacta to maintain a balance of economic success and industry leadership by focusing on quality, innovation, and education.

Show more
Loading
MOVE
Swiss Market Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2025
Call Date
Sep 8, 2025
AI Summary
Q2 2025

Revenue Growth: Medacta reported H1 revenue of EUR 344.1 million, up 19.8% at constant currency and significantly outpacing the market.

Profit Surge: Net profit rose sharply to EUR 60 million, a 58% increase over H1 2024.

Strong Margins: Adjusted EBITDA margin reached 29.6% in constant currency, a 2.7% increase over last year.

Broad-Based Performance: All major product lines and geographies delivered strong growth, with Knees and Extremities up 24% and 44% respectively.

Guidance Confirmed: Full-year guidance for 2025 and midterm outlook were reaffirmed, targeting 16–18% revenue growth and around 28% adjusted EBITDA margin.

Parcus Acquisition Impact: Acquisition contributed positively, with a one-off gain of EUR 12 million, but will dilute EBITDA margin in H2.

CapEx & Cash Flow: CapEx focused mainly on instruments and production expansion; operating cash flow was robust at EUR 73 million, supporting positive free cash flow.

Low Leverage: Company leverage remains low at 0.9x EBITDA.

Key Financials
Revenue
EUR 344.1 million
Adjusted EBITDA Margin
29.6%
Net Profit
EUR 60 million
Gross Profit
EUR 235.1 million
Gross Margin
68.3%
Adjusted EBITDA
EUR 98.8 million
Reported EBITDA
EUR 110.5 million
Operating Cash Flow
EUR 73 million
Free Cash Flow
EUR 8 million
Leverage
0.9x EBITDA
CapEx on Instruments
EUR 36.2 million
CapEx on R&D (capitalized)
EUR 5 million
Earnings Call Recording
Other Earnings Calls
2025
2023

Management

Dr. Alberto Siccardi
Founder & Non Executive Chairman
No Bio Available
Dr. Francesco Siccardi
Chief Executive Officer
No Bio Available
Mr. Corrado Farsetta
Chief Financial Officer
No Bio Available
Gianluca Olgiati
Senior Director of Global Marketing
No Bio Available
Mr. Asif Hussain
Chief People Officer
No Bio Available
Mr. Alessandro Siccardi
Chief Supply Chain Officer
No Bio Available
Filippo Cappelli
Head of IT
No Bio Available
Mr. Giovanni Niccolo Galli
Chief Commercial Officer
No Bio Available
Mr. Massimiliano Bernardoni
Chief Innovation Officer
No Bio Available
Donato Cortesi
Secretary of the Board
No Bio Available

Contacts

Address
TICINO
Castel San Pietro
Strada Regina 34
Contacts